Despina Calamar POPOVICI, Sandra Monica LAZAR, Alina Maria ILIE, Larisa Marina DAVID, Oana SARAU, Dacian Nicolae OROS, Claudiu Octavian IONITA, Sorin Adalbert DEMA, Nicolae Constantin BALICA, Ioana IONITA
Follicular non-Hodgkin Lymphoma (FNHL) is the most common type of indolent non-Hodgkin Lymphomas (NHL) that develops from abnormal B lymphocyte that form follicle-like clusters inside the lymph nodes (1). The prevalence of FNHL is estimated around 1 in 3000 patients, being usually encountered in elderly, 60 years old patients and diagnosed in advanced stages when monoclonal antibodies alone or combined with other chemotherapy agents are needed (2). Recent studies about COVID-19 infection prognosis suggest that oncologic patients are at high risk of morbidity and mortality due to SARS-CoV-2 infection, partially because of the secondary immune deficiency due to malignant pathology itself, but also to the accumulated toxicity secondary to the immuno-chemotherapy treatment. (3). This case report describes a young female patient with FNHL with Bulky abdominal tumoral mass detected at CT scan, in Complete Remission after immune-chemotherapy treatment, contacting COVID-19 twice, first in 2020 and second time in 2022. Even if the patient has been vaccinated against SARS-CoV-2 in late 2021, she did not develop an increased titer of either SPIKE anti-protein neutralizing antibodies (Protein S) or anti-Nucleocapsid IgG antibodies.